• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma) Product Image

Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)

  • ID: 1819670
  • May 2011
  • 5 pages
  • GlobalData

Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)

Summary

The group of cancers that originate in the lymphatic system are known as lymphoma. Lymphoma is broadly classified into two types: Hodgkin lymphoma and non-Hodgkin lymphoma. In 2010, more than 16,887 new cases of Hodgkin lymphoma and 139,507 new cases of non-Hodgkin lymphoma were diagnosed in the top seven markets (the US, the UK, Germany, France, Italy, Spain and Japan). The treatment for Hodgkin lymphoma is dominated by the combination of generic drugs like doxorubicin, bleomycin, vinblastine, dacarbazine, mechlorethamine, etoposide, vincristine, prednisone, cyclophosphamide, procarbazine, chlorambucil, methylprednisolone, cytarabine, cisplatin and dexamethasone. The treatment for non-Hodgkin lymphoma is dominated by Rituxan (rituximab) followed by Velcade (bortezomib), Bexxar (tositumomab and Iodine I 131 tositumomab), Zevalin ([90Y]-ibritumomab tiuxetan), Treanda (bendamustine hydrochloride), Folotyn (pralatrexate) and Mozobil (plerixafor).

Scope

- There is a high unmet need, both in Hodgkin lymphoma READ MORE >

1
1

2 Summary
3 Overview
3.1 Disease Overview
3.2 Epidemiology
3.3 Current Therapy Options
3.4 Unmet Need
3.5 Brentuximab Vedotin – First Drug to Treat Relapsed or Refractory Hodgkin Lymphoma and ALCL patients.
3.6 Current Market
4 Appendix
4.1 Methodology
4.1.1 Coverage
4.1.2 Secondary Research
4.1.3 Primary Research
4.1.4 Expert Panel Validation
4.2 Contact Us
4.3 Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos